The Filing Desk

Champions Oncology vs Q32 Bio

Champions Oncology CSBR · Q32 Bio QTTB · Biotechnology

Champions Oncology reported revenue of $59 million in fiscal 2026, about the same as Q32 Bio's $54 million in fiscal 2025. Champions Oncology had an operating margin of -1.9%, against 31.4% at Q32 Bio. Free cash flow was −$5 million at Champions Oncology and −$34 million at Q32 Bio. Their fiscal years end in different months (April 30 and December 31), so the periods don't line up exactly.

Side by side

Champions OncologyQ32 Bio
Latest fiscal yearFY2026, Apr 30, 2026FY2025, Dec 31, 2025
Revenue$59M$54M
Revenue growth4.4%—
Revenue growth a year, last 5 years7.7%81.9%
Gross margin48.0%—
Operating margin−1.9%31.4%
Net margin−2.0%55.5%
Free cash flow−$5M−$34M
Free cash flow margin−8.5%−62.4%
Return on capital——
Net debt to EBITDA—−2.8x
Dividends and buybacks$0M$0M
Change in diluted share count−3.0%27.5%
Last close$4.40$8.48
P/E at the last close—10.5×
Insider trades, last 12 months——
Piotroski F-score—3 of 8
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Champions OncologyQ32 Bio
Operating margin
Percent of revenue
Champions OncologyQ32 Bio
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Champions OncologyQ32 Bio

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Champions Oncology and Q32 Bio pages.